Samsung Biologics announces tender offer to acquire PolyPeptide Group AG for CHF 44.31 per share
Baar, 20 July 2026 – PolyPeptide Group AG (SIX: PPGN), a specialized global CDMO for peptide-based active pharmaceutical ingredients, today announced Samsung Biologics’ tender offer to acquire PolyPeptide Group AG as well as the successful closing of the first half of 2026 and preliminary results for the period, reflecting a marked acceleration in growth and profitability.
Peter Wilden, Chairman of the Board of Directors of PolyPeptide, said:
“PolyPeptide was built on the dedication of our employees, deep scientific expertise and strong customer focus. After a comprehensive review of strategic options, the Board is convinced that Samsung Biologics’ offer is compelling for our shareholders, delivering an attractive cash price and immediate, certain value today. At the same time, it represents a transformational opportunity to accelerate our strategic ambitions at a scale we could not reach alone – creating a stronger global partner for customers and a platform uniquely positioned to lead the next phase of growth in peptide-based therapeutics.”
[…]